دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 4,800,000 تومان- قیمت ویژه : 2,400,000تومان
پکیج دسترسی ۳ ماهه به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 93 ﺭﻭﺯ
- :
قیمت : 1,500,000 تومان- قیمت ویژه : 750,000تومان
Media Analysis of the Canadian Deemed Consent Policy: Valuable Insights?.
10.2215/CJN.11270922
doi : 10.2215/CJN.11270922
Volume 17(11) pgs. 1575-1706 November 2022
Understanding Public Perspectives on Opt-Out Deceased Donor Transplant Policy: Ethically Obligatory and Practically Necessary.
Butler, Catherine R. 1,2
doi : 10.2215/CJN.11230922
Integrating PROMs in Routine Dialysis Care: The Devil Is in the (Implementation) Details.
Flythe, Jennifer E.
doi : 10.2215/CJN.10840922
The Role of Anti-B Cell Activating Factor Therapy for Treating Lupus Nephritis.
Wooden, Benjamin; Radhakrishnan, Jai
doi : 10.2215/CJN.11340922
Can We Turn the Symptom Curve?: Symptom Trajectories and Outcomes among Patients with CKD.
Rodriguez de Sosa, Giselle 1; Unruh, Mark 1,2
doi : 10.2215/CJN.11240922
Five-Year Symptom Trajectories in Nondialysis-Dependent CKD Patients.
Faye, Moustapha 1; Legrand, Karine 1,2; Le Gall, Lisa 3,4; Leffondre, Karen 3,4; Omorou, Abdou Y. 1,2; Alencar de Pinho, Natalia 5,6; Combe, Christian 7,8; Fouque, Denis 9; Jacquelinet, Christian 10; Laville, Maurice 11; Liabeuf, Sophie 12; Massy, Ziad A. 5,6; Speyer, Elodie 5,6; Pecoits Filho, Roberto 13; Stengel, Benedicte 5; Frimat, Luc 2,14; Ayav, Carole 1,2,*; on behalf of the CKD-REIN Study Group
doi : 10.2215/CJN.06140522
Genome-Wide Association Study for eGFR in a Taiwanese Population.
Chen, Ying-Chun 1,2; Wong, Henry Sung-Ching 3; Wu, Mei-Yi 4,5,6,7,8; Chou, Wan-Hsuan 3; Kao, Chih-Chin 6,8,9; Chao, Ching-Hsuan 3; Chang, Wei-Chiao 1,3,10,11; Wu, Mai-Szu 1,7,8,12
doi : 10.2215/CJN.02180222
Toxic Occupational Exposures and Membranous Nephropathy.
Cremoni, Marion 1,2,3; Agbekodo, Sophie 4; Teisseyre, Maxime 1,2; Zorzi, Kevin 1; Brglez, Vesna 1,2; Benzaken, Sylvia 5; Esnault, Vincent 1,3; Planchard, Jo-Hanna 4; Seitz-Polski, Barbara 1,2,3,5
doi : 10.2215/CJN.02930322
Safety and Efficacy of Belimumab in Patients with Lupus Nephritis: Open-Label Extension of BLISS-LN Study.
Furie, Richard 1; Rovin, Brad H. 2; Houssiau, Frederic 3; Contreras, Gabriel 4; Teng, Y.K. Onno 5; Curtis, Paula 6; Green, Yulia 6; Okily, Mohamed 6; Madan, Anuradha 7; Roth, David A. 7
doi : 10.2215/CJN.02520322
How the Routine Use of Patient-Reported Outcome Measures for Hemodialysis Care Influences Patient-Clinician Communication: A Mixed-Methods Study.
Schick-Makaroff, Kara 1; Wozniak, Lisa A. 2; Short, Hilary 2; Davison, Sara N. 3; Klarenbach, Scott 3; Buzinski, Robert 4; Walsh, Michael 5; Johnson, Jeffrey A. 2
doi : 10.2215/CJN.05940522
: Patient-reported outcome measures invite patients to self-report aspects of their quality of life and have been reported to enhance communication with clinicians.
Longitudinal Evaluation of Donor-Derived Cellfree DNA in Pediatric Kidney Transplantation.
Dandamudi, Raja 1; Gu, Hongjie 2; Goss, Charles W. 2; Walther, Leslie 1; Dharnidharka, Vikas R. 1
doi : 10.2215/CJN.03840322
Longitudinal Evaluation of Donor-Derived Cellfree DNA in Pediatric Kidney Transplantation.
Fox, Danielle E. 1; Donald, Maoliosa 2; Chong, Christy 1; Quinn, Robert R. 1,2; Ronksley, Paul E. 1; Elliott, Meghan J. 1,2; Lam, Ngan N. 1,2
doi : 10.2215/CJN.04340422
Effects of Dapagliflozin in People without Diabetes and with Microalbuminuria.
Heerspink, Hiddo J.L. 1,2; Chertow, Glenn M. 3; Jongs, Niels 1; Correa-Rotter, Ricardo 4; Rossing, Peter 5,6; Sjostrom, C. David 7; Langkilde, Anna Maria 7; Wheeler, David C. 8; for the DAPA-CKD Trial Committee and Investigators
doi : 10.2215/CJN.07290622
Processes of Care in Survivors of Acute Kidney Injury followed in Specialized Postdischarge Clinics.
Ortiz-Soriano, Victor 1; Singh, Gurmukteshwar 2; Chang, Alexander 3; Ruiz, Eloy F. 3; Wald, Ron 4; Silver, Samuel A. 5; Neyra, Javier A. 1,6
doi : 10.2215/CJN.00160122
Correction: Physiology of the Aging Kidney: We Know Where We Are Going, but We Don't Know How[horizontal ellipsis].
doi : 10.2215/CJN.09940822
Acute Kidney Injury in Patients with Liver Disease.
Cullaro, Giuseppe 1; Kanduri, Swetha Rani 2,3; Velez, Juan Carlos Q. 2,3
doi : 10.2215/CJN.03040322
How I Treat Steroid-Sensitive Nephrotic Syndrome in Children.
Vivarelli, Marina; Emma, Francesco
doi : 10.2215/CJN.05200422
Reducing the Risks of Home Dialysis Innovation and Uptake: The Case for Human-Centered Product Design.
Cahill, Zachary 1; Conway, Paul T. 2; Lim, Mark D. 1
doi : 10.2215/CJN.05100422
"Make Me a Match": All-In and Other Trends in the Nephrology Match.
Cheng, Steven C. 1; Pivert, Kurtis A. 2; Sozio, Stephen M. 3,4
doi : 10.2215/CJN.04450422
Gut Microbiome and Kidney Disease: Reconciling Optimism and Skepticism.
Shankaranarayanan, Divya; Raj, Dominic S.
doi : 10.2215/CJN.04480422
Digenic Alport Syndrome.
Savige, Judy 1; Renieri, Alessandra 2,3,4; Ars, Elisabet 5; Daga, Sergio 2,3; Pinto, Anna Maria 4; Rothe, Hansjorg 6; Gale, Daniel P. 7; Aksenova, Marina 8; Cerkauskaite, Agne 9; Bielska, Olga 10; Lipska-Zietkiewicz, Beata 10; Gibson, Joel T. 1
doi : 10.2215/CJN.03120322
AB Digenic Alport syndrome refers to the inheritance of pathogenic variants in COL4A5 plus COL4A3 or COL4A4 or in COL4A3 plus COL4A4. Where digenic Alport syndrome includes a pathogenic COL4A5 variant, the consequences depend on the sex of the affected individual, COL4A5 variant "severity," and the nature of the COL4A3 or COL4A4 change.
